About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2025№1
Managing menopause after cancer: the...

Managing menopause after cancer: the problem and the solution

DOI
https://dx.doi.org/10.18565/aig.2025.8

Dubrovina S.O.

Rostov State Medical University, Ministry of Health of Russia, Moscow, Russia

Advances in the field of oncology have led to significant improvements in the diagnosis and treatment of malignant tumors, resulting in increased survival rates for cancer patients. More and more women live long enough and reach natural menopause, or experience symptoms of premature ovarian failure due to a side effect of cancer therapy. More than nine million women worldwide are diagnosed with cancer each year, and treatment usually leads to early menopause and associated symptoms. The diagnosis of menopause after cancer can be challenging due to the fact that many women start menstruating within two years of completing chemotherapy. The choice of menopausal hormone therapy (MHT) in cancer survivors depends on the type of tumor. In cases when MHT is contraindicated, non-drug and non-hormonal therapies are available for the management of vasomotor symptoms. It is evident that phytoestrogens alone are not sufficient in managing the vasomotor symptoms associated with menopause. Estrovel is a complex of phytoestrogens, vitamins and minerals. It acts as a selective modulator of estrogen receptors and relieves early manifestations of estrogen deficiency, including hot flushes, emotional lability and instability of blood pressure.   
Conclusion: The information presented in this article on the management of menopausal symptoms in patients after cancer of various localizations is intended to assist medical professionals in treating such patients.

Conflicts of interest: The author declares that there are no conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Dubrovina S.O. Managing menopause after cancer: the problem and the solution.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (1): 134-144 (in Russian)
https://dx.doi.org/10.18565/aig.2025.8

Keywords

cancer
menopause
menopausal hormone therapy
MHT
Estrovel
Full text (in Russian)

References

  1. Deli T., Orosz M., Jakab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol. Oncol. Res. 2020; 26(1): 63-78. https://dx.doi.org/10.1007/s12253-018-00569-x.
  2. Zhu D., Chung H.F., Pandeya N., Dobson A.J., Kuh D., Crawford S.L. et al. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur. J. Epidemiol. 2018; 33(8): 699-710. https://dx.doi.org/10.1007/s10654-018-0367-y.
  3. Overbeek A., van den Berg M.H., van Leeuwen F.E., Kaspers G.J., Lambalk C.B., van Dulmen-den Broeder E. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer Treat. Rev. 2017; 53: 10-24. https://dx.doi.org/10.1016/j.ctrv.2016.11.006
  4. Hickey M., Basu P., Sassarini J., Stegmann M.E., Weiderpass E., Nakawala Chilowa K. et al. Managing menopause after cancer. Lancet. 2024; 403(10430): 984-96. https://dx.doi.org/10.1016/S0140-6736(23)02802-7.
  5. Saeaib N., Peeyananjarassri K., Liabsuetrakul T., Buhachat R., Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst. Rev. 2020; 1(1): CD012559. https://dx.doi.org/10.1002/14651858.CD012559.pub2.
  6. Pergialiotis V., Pitsouni E., Prodromidou A., Frountzas M., Perrea D.N., Vlachos G.D. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016; 23(3): 335-42. https://dx.doi.org/10.1097/GME.0000000000000508.
  7. Li D., Ding C.Y., Qiu L.H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol. Oncol. 2015; 139(2): 355-62. https://dx.doi.org/10.1016/j.ygyno.2015.07.109.
  8. Eeles R.A., Morden J.P., Gore M., Mansi J., Glees J., Wenczl M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J. Clin. Oncol. 2015; 33(35): 4138-44. https://dx.doi.org/10.1200/JCO.2015.60.9719.
  9. Brennan A., Brennan D., Rees M., Hickey M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int. J. Gynecol. Cancer. 2021; 31(3): 352-9. https://dx.doi.org/10.1136/ijgc-2020-002032.
  10. Villa P., Bounous V.E., Amar I.D., Bernardini F., Giorgi M., Attianese D. et al. Hormone replacement therapy in post-menopause hormone-dependent gynecological cancer patients: a narrative review. J. Clin. Med. 2024; 13(5): 1443. https://dx.doi.org/10.3390/jcm13051443.
  11. Sinno A.K., Pinkerton J., Febbraro T., Jones N., Khanna N., Temkin S. et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol. Oncol. 2020; 157(2): 303-6. https://dx.doi.org/10.1016/j.ygyno.2020.01.035.
  12. Rees M., Angioli R., Coleman R.L., Glasspool R., Plotti F., Simoncini T. et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56-61. https://dx.doi.org/10.1016/j.maturitas.2020.01.005.
  13. Bourdel N., Huchon C., Abdel Wahab C., Azaïs H., Bendifallah S., Bolze P.A. et al. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF). Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 256: 492-501. https://dx.doi.org/10.1016/j.ejogrb.2020.11.045.
  14. Gershenson D.M. Clinical management potential tumours of low malignancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2002; 16(4): 513-27. https://dx.doi.org/10.1053/beog.2002.0308.
  15. Silverberg S.G., Bell D.A., Kurman R.J., Seidman J.D., Prat J., Ronnett B.M. et al. Borderline ovarian tumors: key points and workshop summary. Hum. Pathol. 2004; 35(8): 910-7. https://dx.doi.org/10.1016/j.humpath.2004.03.003.
  16. Seidman J.D., Soslow R.A., Vang R., Berman J.J., Stoler M.H., Sherman M.E. et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum. Pathol. 2004; 35(8): 918-33. https://dx.doi.org/10.1016/j.humpath.2004.03.004.
  17. Bodner K., Laubichler P., Kimberger O., Czerwenka K., Zeillinger R., Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 2010; 30(4): 1341-5.
  18. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 1987; 26(2): 169-77. https://dx.doi.org/10.1016/0090-8258(87)90270-8.
  19. Lacey J.V. Jr., Brinton L.A., Barnes W.A., Gravitt P.E., Greenberg M.D., Hadjimichael O.C. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 2000; 77(1): 149-54. https://dx.doi.org/10.1006/gyno.2000.5731.
  20. Richardson A., Watson L., Persic M., Phillips A. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post. Reprod. Health. 2021; 27(3):167-73. https://dx.doi.org/10.1177/20533691211028518.
  21. Lee S.H., Cho Y.J., Cho K.J., Ko M.H., Jung S.Y., Chon S.J. et al. Effect of tibolone on the survival of early stage cervical adenocarcinoma patients. Obstet. Gynecol. Sci. 2018; 61(5): 584-9. https://dx.doi.org/10.5468/ogs.2018.61.5.584.
  22. Di Donato V., Palaia I., D'Aniello D., Musacchio L., Santangelo G., Di Mauro F. et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review. Oncology. 2020; 98(4): 195-201. https://dx.doi.org/10.1159/000505427.
  23. Finch A., Evans G., Narod S.A. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond.). 2012; 8(5): 543-55. https://dx.doi.org/10.2217/whe.12.41.
  24. Poggio F., Del Mastro L., Bruzzone M., Ceppi M., Razeti M.G., Fregatti P. et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2022; 191(2): 269-75. https://dx.doi.org/10.1007/s10549-021-06436-9.
  25. Edey K.A., Rundle S., Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst. Rev. 2018; 5(5): CD008830. https://dx.doi.org/10.1002/14651858.CD008830.pub3.
  26. Cibula D., Pötter R., Planchamp F., Åvall-Lundqvist E., Fischerová D., Haie Meder C. et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int. J. Gynecol. Cancer 2018; 28: 641-55. https://dx.doi.org/10.1097/IGC.000000000000001216.
  27. Yang X., Wang C., He X., Wei J., Wang Y., Li X. et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric. 2017; 20(3): 268-73. https://dx.doi.org/10.1080/13697137.2017.1309382.
  28. MacKie R.M., Bray C.A. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br. J. Cancer. 2004; 90(4): 770-2. https://dx.doi.org/10.1038/sj.bjc.6601595.
  29. Chan J.A., Meyerhardt J.A., Chan A.T., Giovannucci E.L., Colditz G.A., Fuchs C.S. Hormone replacement therapy and survival after colorectal cancer diagnosis. J. Clin. Oncol. 2006; 24(36): 5680-6. https://dx.doi.org/10.1200/JCO.2006.08.0580.
  30. Ji J., Sundquist J., Sundquist K. Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: A population-based study in Sweden. Int. J. Cancer. 2018; 142(10): 2003-10. https://dx.doi.org/10.1002/ijc.31228.
  31. Hassan M.M., Botrus G., Abdel-Wahab R., Wolff R.A., Li D., Tweardy D. et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2017; 15(11): 1791-9. https://dx.doi.org/10.1016/j.cgh.2017.05.036.
  32. Brennan A., Rees M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2021; 35(6): 101575. https://dx.doi.org/10.1016/j.beem.2021.101575.
  33. Zhang X., Du Y., Tan X., Wang H., Li Y., Zhang Z. et al. The relationship between hormone replacement therapy and risk of kidney cancer in women: a meta-analysis. Cancer Control. 2020; 27(2): 1073274820930194. https://dx.doi.org/10.1177/1073274820930194.
  34. Clague J., Reynolds P., Henderson K.D., Sullivan-Halley J., Ma H., Lacey J.V. Jr. et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study. PLoS One. 2014; 9(7): e103735. https://dx.doi.org/10.1371/journal.pone.0103735.
  35. Katcoff H., Wenzlaff A.S., Schwartz A.G. Survival in women with NSCLC: the role of reproductive history and hormone use. J. Thorac. Oncol. 2014; 9(3): 355-61. https://dx.doi.org/10.1097/JTO.0000000000000077.
  36. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 2006; 24(1): 59-63. https://dx.doi.org/10.1200/JCO.2005.02.9827.
  37. Chlebowski R.T., Schwartz A.G., Wakelee H., Anderson G.L., Stefanick M.L., Manson J.E. et al.; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009; 374(9697): 1243-51. https://dx.doi.org/10.1016/S0140-6736(09)61526-9.
  38. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213.
  39. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33. https://dx.doi.org/10.1001/jama.288.3.321.
  40. Ossewaarde M.E., Bots M.L., Verbeek A.L., Peeters P.H., van der Graaf Y., Grobbee D.E. et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005; 16(4): 556-62. https://dx.doi.org/10.1097/01.ede.0000165392.35273.d4.
  41. van der Schouw Y.T., van der Graaf Y., Steyerberg E.W., Eijkemans J.C., Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 347(9003): 714-8. https://dx.doi.org/10.1016/s0140-6736(96)90075-6.
  42. de Villiers T.J., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D. et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4. https://dx.doi.org/10.3109/13697137.2013.771520.
  43. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166.
  44. Табеева Г.И., Сметник А.А., Ермакова Е.И. Принципы применения негормональных средств с целью коррекции климактерических нарушений: до, вместо или вместе с менопаузальной гормональной терапией. Акушерство и гинекология. 2023; 9: 192-8. [Tabeeva G.I., Smetnik А.А., Ermakova E.I. The use of non-hormonal medications for the correction of menopausal disorders: before, instead or together with menopausal hormone therapy.Obstetrics and Gynecology. 2023; (9): 192-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.210.
  45. Хаджиева Н.Х., Алиева А.М., Никитин И.Г. Биологическое и хронологическое старение. Пути замедления старения. Акушерство и гинекология. 2024; 8: 40-6. [Khadzhieva N.Kh., Alieva A.M., Nikitin I.G. Biological and chronological aging. Ways to slow down aging. Obstetrics and Gynecology. 2024; (8): 40-6 (in Russian)]. https://dx.doi.org/10.18565/aig.2024.167.
  46. Mu Y., Kou T., Wei B., Lu X., Liu J., Tian H. et al. Soy products ameliorate obesity-related anthropometric indicators in overweight or obese Asian and non-menopausal women: a meta-analysis of randomized controlled trials. Nutrients. 2019; 11(11): 2790. https://dx.doi.org/10.3390/nu11112790.
  47. Setchell K.D.R. The history and basic science development of soy isoflavones. Menopause. 2017; 24(12): 1338-50. https://dx.doi.org/10.1097/GME.0000000000001018.
  48. Lephart E.D. Modulation of aromatase by phytoestrogens. Enzyme Res. 2015; 2015: 594656. https://dx.doi.org/10.1155/2015/594656.
  49. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. Int. J. Vitam. Nutr. Res. 2003; 73(2): 120-6. https://dx.doi.org/10.1024/0300-9831.73.2.120.
  50. Nachvak S.M., Moradi S., Anjom-Shoae J., Rahmani J., Nasiri M., Maleki V. et al. Soy, soy isoflavones, and protein intake in relation to mortality from all causes, cancers, and cardiovascular diseases: a systematic review and dose-response meta-analysis of prospective cohort studies. J. Acad. Nutr. Diet. 2019; 119(9): 1483-1500.e17. https://dx.doi.org/10.1016/j.jand.2019.04.011.
  51. Shu X.O., Zheng Y., Cai H., Gu K., Chen Z., Zheng W. et al. Soy food intake and breast cancer survival. JAMA. 2009; 302(22): 2437-43. https://dx.doi.org/10.1001/jama.2009.1783.

Received 16.01.2025

Accepted 26.01.2025

About the Authors

Svetlana O. Dubrovina, Professor, Dr. Med. Sci., Chief Researcher at Rostov State Medical University, Ministry of Health of Russia; Chief Researcher at Scientific Research Institute of Obstetrics and Pediatrics, 344012, Russia, Rostov-on-Don, Mechnikov str, 43, +7(863)250-42-00, s.dubrovina@gmail.com

Similar Articles

№4 / 2023
Gasparyan S.A., Chotchaeva A.M., Karpov S.M.
Effectiveness of early start of menopausal hormone therapy in the menopausal transition: comparative analysis of therapy
№8 / 2023
Panevin T.S., Smetnik A.A.
Menopause in rheumatology: what is important for gynecologist to know?
№9 / 2024
Kurbanova P.F., Ermakova E.I., Priputnevich T.V.
Compositional features of the gut microbiota in perimenopausal and postmenopausal women
№6 / 2024
Yashchuk A.G., Dautova L.A., Shaikhutdinova O.V., Muslimova L.R., Berg P.A., Berg E.A., Nasyrova S.F., Kizko I.A., Nazyrova A.G.
Possibilities of the biologically active complex of phytopreparations in the correction of menopausal disorders
№9 / 2024
Yureneva S.V.
Efficacy and safety of personalized menopausal hormone therapy: a review of international guidelines
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.